Talphera
TLPH

$0.9414

4.6%

Market Cap: $16M

About: Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Employees: 15

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

24% more capital invested

Capital invested by funds: $4.57M [Q1] → $5.64M (+$1.08M) [Q2]

11.19% more ownership

Funds ownership: 26.13% [Q1] → 37.32% (+11.19%) [Q2]

6% less funds holding

Funds holding: 31 [Q1] → 29 (-2) [Q2]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$6

537%

upside

Avg. target

$6

537%

upside

High target

$6

537%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Ed Arce

44% 1-year accuracy

60 / 136 met price target

537%upside

$6

Buy

Reiterated

16 Aug 2024

See Analyst Rankings

Financial journalist opinion

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

SAN MATEO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C.

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein, a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif. , Aug. 19, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study.

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Talphera, Inc. (NASDAQ:TLPH ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Founder and Chief Medical Officer Conference Call Participants Ed Arce - H.C. Wainwright Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Welcome to Talphera's Second Quarter 2024 Financial Results Conference Call.

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif. , Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update.

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

SAN MATEO, Calif. , Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2024 financial results after market close on Wednesday, August 14, 2024, then host a live webcast and conference call at 4:30 p.m.

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif. , May 20, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted inducement awards consisting of a non-statutory time-based stock option to purchase 185,000 shares of common stock and a time-based restricted stock unit award for 32,000 shares of common stock on May 20, 2024 to Dr. Shakil Aslam in connection with his appointment as the Chief Development Officer of Talphera in May 2024.

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Talphera to Participate at A.G.P. Virtual Healthcare Conference

SAN MATEO, Calif. , May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P.

Talphera to Participate at A.G.P. Virtual Healthcare Conference

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

Talphera, Inc. (NASDAQ:TLPH ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Founder and Chief Medical Officer Conference Call Participants Ed Arce - H.C. Wainwright James Molloy - Alliance Global Partners Operator Welcome to the Talphera First Quarter 2024 Financial Results Conference Call.

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talphera as Chief Development Officer Cash and investments at March 31, 2024 of $18.6 million Conference call and webcast to be held Tuesday, May 14, 2024 at 4:30 pm ET SAN MATEO, Calif. , May 14, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2024 financial results and provided a corporate update.

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

SAN MATEO, Calif., May 2, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2024 financial results after market close on Tuesday, May 14, 2024, then host a live webcast and conference call at 4:30 p.m.

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

See News Rankings